Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Is ABO Blood Group a CV Risk Factor in FH Patients?

J Clin Lipidol; ePub 2017 Dec 13; Paquette, et al

A non-O blood group is associated with an independent 2-fold increased risk of cardiovascular disease (CVD) in patients with familial hypercholesterolemia (FH), a recent study found. The study examined the effect of the ABO blood group on CVD risk in 668 adult participants with a heterozygous FH-causing mutation in the low-density lipoprotein receptor (LDLR) gene. ABO blood group was determined using 2 functional single-nucleotide polymorphisms in the ABO gene. Researchers found:

  • Total cholesterol was significantly higher in non-O subjects compared to carriers of the O group.
  • A greater proportion of participants carrying the non-O groups was observed in patients with CVD vs those without CVD (73.4% vs 63.3%).
  • The non-O group was significantly associated with an increased prevalence of CVD (odds ratio, 2.14).
  • Patients in the non-O blood group experienced more CVD events vs those in the O group (0.88 per individual vs 0.60).

Citation:

Paquette M, Dufour R, Baass A. ABO blood group is a cardiovascular risk factor in patients with familial hypercholesterolemia. [Published online ahead of print December 13, 2017]. J Clin Lipidol. doi:10.1016/j.jacl.2017.12.001.

This Week's Must Reads

Omega-3 Fatty Acids for Prevention of CVD, Cochrane Library; ePub 2018 Jul 18; Abdelhamid, et al

Elevated hs-CRP Among Patients with Prior MI, Am Heart J; ePub 2018 Jul 26; Pagidipati, et al

Catheter Ablation for Ventricular Arrhythmias, Am J Cardiol; ePub 2018 Jul 18; Ogunbayo, et al

PIs and CV Outcomes in Patients with HIV and HF, J Am Coll Cardiol; 2018 Jul; Alvi, Neilan, et al

Hypertension in Blacks Higher Through Middle Age, J Am Heart Assoc; ePub 2018 Jul 11; Thomas, et al

Must Reads in Hypercholesterolemia

Racial Differences in Statin Use, JAMA Cardiol; ePub 2018 Jun 13; Nanna, et al

LLT Use in Patients with Elevated LDL-C, Circ Cardiovasc Qual Outcomes; ePub 2018 May 10; Virani, et al

Evolocumab in Differing Patient Populations , J Pharmacokinet Pharmacodyn; ePub 2018 May 7; Kuchimanchi, et al

LDL-C Targets in Elderly Statin Users After ACS, J Am Heart Assoc; ePub 2018 May 12; Alter, et al

Patient Perspectives on Statin Therapy, Clin Cardiol; ePub 2018 May 10; Brinton